HC Wainwright Has Bullish Forecast for RARE Q3 Earnings

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) – Investment analysts at HC Wainwright lifted their Q3 2026 earnings per share estimates for Ultragenyx Pharmaceutical in a research report issued to clients and investors on Monday, August 10th. HC Wainwright analyst R. Selvaraju now forecasts that the biopharmaceutical company will post earnings of $0.75 per share for the quarter, up from their previous forecast of ($0.84). HC Wainwright currently has a “Buy” rating and a $50.00 price objective on the stock. The consensus estimate for Ultragenyx Pharmaceutical’s current full-year earnings is ($4.42) per share. HC Wainwright also issued estimates for Ultragenyx Pharmaceutical’s Q4 2026 earnings at $0.78 EPS, FY2026 earnings at ($1.18) EPS, Q1 2027 earnings at $0.06 EPS, Q2 2027 earnings at $0.91 EPS, Q3 2027 earnings at $1.25 EPS, Q4 2027 earnings at $2.27 EPS and FY2027 earnings at $4.50 EPS.

RARE has been the topic of several other research reports. Wedbush lowered their price target on shares of Ultragenyx Pharmaceutical from $27.00 to $26.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 6th. Barclays cut their price objective on shares of Ultragenyx Pharmaceutical from $44.00 to $43.00 and set an “overweight” rating for the company in a report on Wednesday, April 29th. Cantor Fitzgerald boosted their target price on shares of Ultragenyx Pharmaceutical from $84.00 to $96.00 and gave the company an “overweight” rating in a report on Thursday, May 21st. Guggenheim lowered their target price on shares of Ultragenyx Pharmaceutical from $43.00 to $35.00 and set a “buy” rating on the stock in a report on Tuesday, August 4th. Finally, Wall Street Zen upgraded Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Saturday. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $57.82.

Ultragenyx Pharmaceutical Stock Up 0.6%

NASDAQ RARE opened at $26.96 on Wednesday. The company has a market cap of $2.66 billion, a PE ratio of -4.62 and a beta of 0.35. Ultragenyx Pharmaceutical has a 52 week low of $18.29 and a 52 week high of $39.89. The firm’s 50-day simple moving average is $28.07 and its two-hundred day simple moving average is $24.87.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported ($0.90) earnings per share for the quarter, topping the consensus estimate of ($1.22) by $0.32. Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 81.79%.The company had revenue of $214.00 million during the quarter, compared to analyst estimates of $183.08 million. During the same quarter last year, the firm posted ($1.17) EPS. The firm’s revenue for the quarter was up 28.5% on a year-over-year basis.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in RARE. Parallel Advisors LLC raised its position in shares of Ultragenyx Pharmaceutical by 778.4% in the first quarter. Parallel Advisors LLC now owns 1,625 shares of the biopharmaceutical company’s stock worth $34,000 after buying an additional 1,440 shares in the last quarter. Leonteq Securities AG grew its position in Ultragenyx Pharmaceutical by 288.5% during the first quarter. Leonteq Securities AG now owns 1,795 shares of the biopharmaceutical company’s stock worth $38,000 after buying an additional 1,333 shares in the last quarter. Versant Capital Management Inc increased its stake in Ultragenyx Pharmaceutical by 662.9% in the 2nd quarter. Versant Capital Management Inc now owns 1,152 shares of the biopharmaceutical company’s stock worth $38,000 after acquiring an additional 1,001 shares during the last quarter. Danske Bank A S bought a new position in Ultragenyx Pharmaceutical in the 3rd quarter worth about $39,000. Finally, EverSource Wealth Advisors LLC raised its holdings in shares of Ultragenyx Pharmaceutical by 573.0% in the 1st quarter. EverSource Wealth Advisors LLC now owns 2,167 shares of the biopharmaceutical company’s stock valued at $45,000 after acquiring an additional 1,845 shares in the last quarter. Institutional investors own 97.67% of the company’s stock.

Insider Buying and Selling

In other news, Director Shehnaaz Suliman sold 5,740 shares of the stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $25.12, for a total value of $144,188.80. Following the sale, the director directly owned 27,951 shares of the company’s stock, valued at approximately $702,129.12. This represents a 17.04% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Howard Horn sold 4,653 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $23.77, for a total transaction of $110,601.81. Following the completion of the transaction, the chief financial officer owned 105,689 shares of the company’s stock, valued at $2,512,227.53. This trade represents a 4.22% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 14,292 shares of company stock valued at $351,644. Corporate insiders own 5.20% of the company’s stock.

Key Headlines Impacting Ultragenyx Pharmaceutical

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: HC Wainwright maintained a “Buy” rating and $50 price target. The target remains substantially above the reference price of $26.96, signaling that the analyst sees significant value in Ultragenyx’s rare-disease pipeline and commercial growth prospects. A broader brokerage survey places the average price target at $57.82. Brokerages Set Ultragenyx Pharmaceutical Price Target
• Positive Sentiment: HC Wainwright sharply improved its near-term earnings outlook. The firm raised its Q3 2026 EPS estimate from a loss of $0.84 to a profit of $0.75, increased Q4 2026 EPS from a loss of $0.35 to $0.78, and narrowed its FY2026 loss forecast from $4.27 to $1.18 per share. These changes suggest stronger operating performance or improved revenue timing than previously expected.
• Positive Sentiment: Ultragenyx recently delivered better-than-expected quarterly results. Revenue rose 28.5% year over year to $214 million, exceeding estimates, while the quarterly loss of $0.90 per share was narrower than the expected $1.22 loss. Continued revenue growth could support the improving earnings outlook. Ultragenyx Q2 Revenue Growth and Narrower Loss
• Neutral Sentiment: Ultragenyx and Baylor Research Institute settled a DOJOLVI generic patent lawsuit with Esjay Pharma. The settlement removes some legal uncertainty surrounding the product, but the available report does not disclose the terms, launch timing, or financial impact. DOJOLVI Generic Patent Lawsuit Settlement
• Negative Sentiment: HC Wainwright reduced multiple 2027 EPS forecasts. FY2027 EPS was cut from $5.61 to $4.50, while Q1, Q2, Q3 and Q4 2027 estimates were also lowered. Although the firm still expects a return to profitability, the revisions indicate lower anticipated earnings momentum over the longer term.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.